-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3116 Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center – a Comparative Cohort Study

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, non-Hodgkin lymphoma, epidemiology, Lymphomas, Clinical Research, B Cell lymphoma, health outcomes research, Diseases, aggressive lymphoma, real-world evidence, young adult , Adverse Events, Lymphoid Malignancies, survivorship, Human, Study Population
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Allison M Lehanka1*, Ann Kebede, MD2, Neda Amirmokhtari, MD3*, Joseph R Stanek, MS4*, Narendranath Epperla, MD, MS5, Beth Christian, MD6, Robert Baiocchi, MD7, Timothy Voorhees, MD, MSCR6, Kami J. Maddocks, MD8, Yazeed Sawalha, MD6, John C Reneau, MD, PhD6, Jonathan E. Brammer, MD6, Audrey M. Sigmund, MD6, Faye Willen9*, Nick Yeager, MD10*, Anthony N. Audino, MD11 and David A. Bond, MD, BS12

1The Ohio State University College of Medicine, Columbus, OH
2The Hitchcock Wilson Pediatric Hematology/Oncology/BMT Fellowship, Nationwide Children’s Hospital, Columbus, OH
3Department of Internal Medicine, The Ohio State University, Columbus, OH
4Division of Biostatistics, Nationwide Children's Hospital, Columbus, OH
5The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
6The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
7Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
8The James Cancer Center, Ohio State University Hospital, Columbus, OH
9Nationwide Children's Hospital, Columbus, OH
10Division of Hematology, Oncology, and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, OH
11Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH
12Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

Introduction: Standard treatment regimens for pediatric and adult patients with mature B-cell lymphomas vary significantly. For adolescent or young adult (AYA) patients, who may be candidates for either pediatric or adult regimens, limited data are available regarding comparative toxicities and efficacy for adult versus pediatric therapies.

Methods: A retrospective review was completed for individuals aged 12-39 years at diagnosis with aggressive mature B-cell lymphomas seen between 2011 to 2023 at Ohio State University Comprehensive Care Center (adult cohort) and Nationwide Children’s Hospital (pediatric cohort). Diagnoses included diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL), Burkitt lymphoma (BL), primary mediastinal B cell lymphoma (PMBCL), grey zone lymphoma (GZL), and unclassifiable high-grade B cell lymphoma (HGBCL). Progression free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method and compared by log-rank test. Differences between adult and pediatric cohort were compared using Fisher’s exact test and Chi-squared test. Cox regression model was used to identify prognostic factors for PFS.

Results: Among 180 eligible AYA patients, 156 were treated at the adult center and 24 at the pediatric center. The median age was 30 years (median 15 pediatric [range 12-18] and 31 adult [range 21-39; p<0.001]). Other characteristics included male sex in 75% of pediatric vs 65% adult patients (p=0.3), stage 4 disease in 25% vs 47% (p<0.001), CNS involvement in 8.3% vs 5.4% (p=0.6), and LDH >2x upper limit of normal in 21% vs 31% (p=0.2). The overall median follow-up was 4.8 years (4.5 vs 4.8, p=0.7). Adult center histology included DLBCL (95); DHL (9); BL (8); PMBCL (31); GZL (4); and HGBCL (9). Pediatric diagnoses were DLBCL (13); BL (8); PMBCL (2); and HGBCL (1).

The most common treatments included R-CHOP (57), R-EPOCH (56), RM-CHOP (20), and R-CODOX-M/R-IVAC (16) at the adult center and CCG5961 (7), ANHL1131 (15), and ANHL0221 (1) protocols at the pediatric center. CCG5961 Group B protocol includes pre-phase, induction, and consolidation phases of COP, COPADM, and CYM. Group C includes the same pre-phase and induction, except for higher doses of MTX, with CYVE consolidation with high-dose MTX and randomization to 1 or 4 cycles of maintenance. ANHL1131 protocol was like CCG5961; major differences include randomization to receive rituximab during induction and consolidation and 2 cycles of maintenance for group C patients. ANHL0221, a PTLD protocol, involves 2 cycles of cyclophosphamide, prednisone, and rituximab followed by 4 cycles of cyclophosphamide and prednisone.

A greater incidence of unplanned hospitalization (79% pediatric vs 50% adult, p=0.007), grade 3 mucositis (38% vs 12%, p=0.005), febrile neutropenia (67% vs 44%, p=0.035), and fungal infections (25% vs 3%, p<0.001) were observed for the pediatric cohort (Table 1). Patients in the adult cohort were more likely to receive radiation therapy (26% vs 0%, p=0.004) and experience neuropathy at last follow-up (22% v 0%, p=0.009). Among all patients, other adverse events during follow-up included diagnosis of depression/anxiety (93), heart failure (16), impaired renal function (20), and secondary malignancy (6) (Table 1).

For the total population, 2-year PFS was 78% (88% pediatric vs 77% adult, p=0.35), and 2-year OS was 93% (96% vs 92%, p=0.31).

For patients with DLBCL or DHL, there was a trend towards improved PFS in the pediatric versus adult cohort (p=0.06, Figure 1), and on univariable analysis a trend towards lower risk for progression with receipt of a more intensive regimen compared with R-CHOP/R-MCHOP (hazard ratio 0.46, 95% confidence interval 0.2-1.1, p=0.07).

Conclusions: We observed a higher incidence of short-term adverse effects including severe mucositis, febrile neutropenia, and fungal infection, but lower rates of radiation consolidation and ongoing neuropathy in AYA patients with aggressive mature B-cell lymphoma treated with pediatric versus adult regimens. Relatively higher dose intensity (compared to adult treatments), standard use of CNS prophylaxis, and lower dosage of vinca-alkaloids likely account for the greater incidence of short-term adverse effects and lower rates of neuropathy seen in patients treated at pediatric centers. Further study is needed to evaluate differences in efficacy between treatment approaches in AYA patients with DLBCL/DHL.

Disclosures: Epperla: Incyte: Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Research Funding, Speakers Bureau. Christian: Genentech: Research Funding; Acerta: Research Funding; Millenium: Research Funding; BMS: Research Funding; F Hoffman-La Roche: Research Funding. Baiocchi: Prelude Therapeutics: Consultancy; EUSA: Consultancy; Viracta: Membership on an entity's Board of Directors or advisory committees; Atara Biotherapeutics: Membership on an entity's Board of Directors or advisory committees. Voorhees: Recordati: Consultancy, Research Funding; Morphosys: Research Funding; Incyte: Research Funding; AstraZeneca: Research Funding; Novartis: Consultancy. Maddocks: Janssen: Consultancy, Honoraria; Eli Lilly and Company: Consultancy; Seattle Genetics: Consultancy; Novartis: Research Funding; BMS: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; BeiGene: Consultancy; Epizyme: Consultancy; Gilead/Kite: Consultancy; Morphosys: Consultancy; Pharmacyclics: Consultancy, Research Funding; GenMab: Consultancy; Merck: Research Funding; Incyte: Consultancy, Honoraria; Genentech: Consultancy; ADC Therapeutics: Consultancy; Celgene: Consultancy, Research Funding; AbbVie: Consultancy. Sawalha: Celgene/BMS: Research Funding; Beigene: Research Funding; TG Therapeutics: Research Funding. Brammer: Verastem: Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kymera: Consultancy; Incyte: Research Funding; Dren Bio: Consultancy; Bristol Myers Squibb: Research Funding. Bond: Novartis: Consultancy, Research Funding; SeaGen: Consultancy; Incyte: Research Funding; Nurix Therapeutics: Consultancy, Research Funding.

*signifies non-member of ASH